DCM
PCRX icon

Driehaus Capital Management’s Pacira BioSciences PCRX Stock Holding History

Driehaus Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-217,752
Closed -$11.6M – 395
2022
Q3 		$11.6M Sell
217,752
-36,995
-15% -$2.06M 0.18% 173
2022
Q2 		$14.9M Sell
254,747
-86,453
-25% -$5.66M 0.24% 143
2022
Q1 		$26M Buy
+341,200
New +$22.7M 0.32% 105
2020
Q4 		– Sell
-121,069
Closed -$7.28M – 449
2020
Q3 		$7.28M Buy
+121,069
New +$7.03M 0.15% 172
2016
Q1 		– Sell
-47,599
Closed -$3.65M – 619
2015
Q4 		$3.65M Buy
47,599
+34,755
+271% +$1.97M 0.12% 186
2015
Q3 		$528K Sell
12,844
-688
-5% -$42.1K 0.02% 423
2015
Q2 		$957K Sell
13,532
-40,902
-75% -$3.22M 0.03% 414
2015
Q1 		$4.84M Sell
54,434
-36,764
-40% -$3.73M 0.17% 150
2014
Q4 		$8.09M Buy
91,198
+25,189
+38% +$2.38M 0.33% 72
2014
Q3 		$6.4M Buy
66,009
+32,575
+97% +$3.17M 0.24% 109
2014
Q2 		$3.07M Buy
+33,434
New +$2.55M 0.1% 276
2013
Q4 		– Sell
-35,780
Closed -$1.72M – 511
2013
Q3 		$1.72M Buy
35,780
+6,983
+24% +$254K 0.07% 295
2013
Q2 		$835K Buy
+28,797
New +$833K 0.04% 358

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Driehaus Capital Management's PCRX Position: Q4 2022 in Review

Driehaus Capital Management sold out of Pacira BioSciences (PCRX) in Q4 2022, closing a stake of 217,752 shares — an estimated $11.6M sold.

Driehaus Capital Management first reported a position in PCRX in Q2 2013 and held it in 13 quarters. The position peaked at $26M in Q1 2022. 273 funds tracked by Wall St. Rank hold PCRX as of Q4 2022.

  • Driehaus Capital Management reported no remaining Pacira BioSciences position as of Q4 2022 after selling out during the quarter.
  • Driehaus Capital Management sold 217,752 Pacira BioSciences shares in Q4 2022, an estimated $11.6M.
  • Driehaus Capital Management first reported a position in Pacira BioSciences in Q2 2013 and held it in 13 quarters.
  • Driehaus Capital Management's Pacira BioSciences position peaked at $26M in Q1 2022.
  • 273 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2022.

Based on Driehaus Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.